GlaxoSmithkline Pharmaceuticals Ltd.

BSE: GLAXO500660ISIN INE159A01016

Healthcare
Pharmaceuticals
BSE 200

Share price

₹2,532.60-40.70 (-1.58%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

52W high: ₹3,121.10
52W low: ₹2,088.00
Off 52W high: -18.86%
1M return: -7.37%
3M return: -1.32%
6M return: +4.47%
1Y return: -4.84%
20D avg volume: 2,804
50 DMA: ₹2,740.11
200 DMA: ₹2,515.42

Key ratios Consolidated

Market cap: ₹42,904 Cr
Current price: ₹2,532.60
52W high / low: ₹3,121.10 / ₹2,088.00
Face value: ₹10.00
P/E: 37.42
P/B: 22.81
EPS (TTM): ₹67.68
Book value / share: ₹111.04
ROE: —
ROCE: 55.40%
Operating margin: —
Net margin: —
Debt / equity: 0.00
Net debt: ₹-1,102 Cr
Interest cover: 516.02
Dividend yield: 2.25%
Dividend / share (TTM): ₹57.00
Payout: 84.22%
Cash conversion cycle: 15.3 days

Financials

Metric	Q2 FY27	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24
Income statement
	1,184	938.44	995.30	1,041	979.94	805.17	974.37	949.42	1,011	814.65	929.80	805.26
	72.78	43.76	35.95	32.12	33.57	43.72	40.68	35.07	34.54	35.64	29.83	28.11
	1,256	982.20	1,031	1,073	1,014	848.89	1,015	984.49	1,045	850.29	959.63	833.37
	797.01	659.75	658.15	691.43	662.15	569.91	656.48	676.39	706.19	600.89	691.41	604.63
	128.92	72.95	113.06	79.90	115.13	128.06	115.23	97.48	148.96	138.23	204.60	90.95
	279.04	378.62	228.40	217.27	232.72	232.06	291.40	164.23	216.74	172.74	255.74	162.52
	170.19	159.04	164.75	151.88	138.05	152.57	152.97	124.74	150.71	151.28	172.83	141.35
	0.49	0.97	0.61	1.19	0.51	0.42	0.58	0.09	0.27	0.37	0.77	0.32
	15.02	15.84	13.17	20.32	17.43	15.52	14.72	18.80	16.86	16.41	18.10	17.11
	166.83	155.96	135.62	154.22	150.63	113.69	136.27	173.60	153.86	137.56	132.58	129.01
	459.34	322.45	373.10	381.95	351.36	278.98	358.57	308.10	339.12	249.40	268.22	228.74
	0.00	0.00	0.00	17.98	2.64	0.00	0.00	0.00	4.69	0.00	2.40	-163.31
	459.34	322.45	373.10	399.93	354.00	278.98	358.57	308.10	343.81	249.40	270.62	65.43
	123.46	85.27	95.24	104.31	96.51	73.97	95.70	78.22	91.31	67.07	76.14	19.71
	335.88	237.18	277.86	295.62	257.49	205.01	262.87	229.88	252.50	182.33	194.48	45.72
	19.83	14.00	16.40	16.54	15.07	12.10	15.52	13.57	14.67	10.76	11.48	9.89
Key metrics
	474.85	339.26	386.88	421.44	371.94	294.92	373.87	326.99	360.94	266.18	289.49	82.86
	40.10%	36.20%	38.90%	40.50%	38.00%	36.60%	38.40%	34.40%	35.70%	32.70%	31.10%	10.30%
	28.40%	25.30%	27.90%	28.40%	26.30%	25.50%	27.00%	24.20%	25.00%	22.40%	20.90%	5.70%
	21.30%	—	14.70%	—	17.80%	—	16.30%	—	—	—	—	—
	20.80%	16.60%	2.10%	9.70%	-3.10%	-1.20%	4.80%	17.90%	—	—	—	—
	30.40%	15.70%	5.70%	28.60%	2.00%	12.40%	35.20%	402.80%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18
Income statement
	4,159	3,822	3,749	3,454	3,252	3,278	3,199	3,224	3,128	2,896
	184.61	145.36	145.93	122.59	100.66	75.78	110.58	79.01	102.32	54.54
	4,343	3,967	3,895	3,576	3,352	3,354	3,309	3,303	3,230	2,950
	2,806	2,582	2,640	2,616	2,515	2,586	2,586	2,656	2,576	2,428
	394.83	436.15	499.90	545.17	427.48	611.18	472.02	474.38	686.57	510.82
	1,103	910.45	845.11	853.08	788.43	729.44	880.11	868.92	645.89	788.42
	645.86	607.25	579.70	624.39	594.99	610.23	614.69	628.55	537.20	523.40
	3.26	2.73	1.31	1.80	1.81	2.00	3.53	6.34	0.55	0.19
	64.35	66.44	66.79	69.68	65.77	68.19	79.28	82.68	48.59	—
	612.63	554.16	601.29	586.10	567.57	549.73	576.14	630.71	632.10	600.94
	1,537	1,385	1,255	959.80	837.37	767.47	723.10	647.24	653.97	522.17
	17.98	20.62	4.69	-143.61	-0.97	11.58	-172.60	-341.49	28.69	17.80
	1,555	1,406	1,260	816.19	836.40	779.05	550.50	305.75	682.66	539.97
	408.28	370.03	332.30	226.23	228.76	398.28	192.35	212.55	237.27	189.25
	1,147	1,036	927.58	589.96	610.69	1,695	358.15	93.20	445.39	350.72
	66.77	54.52	54.52	34.83	35.87	22.48	21.14	5.50	26.29	—
Key metrics
	1,622	1,475	1,328	887.67	903.98	849.24	633.31	394.77	731.80	540.16
	39.01%	38.60%	35.40%	25.70%	27.80%	25.90%	19.80%	12.20%	23.40%	18.70%
	27.57%	27.10%	24.70%	17.10%	18.80%	51.70%	11.20%	2.90%	14.20%	12.10%
	—	55.40%	57.30%	—	—	—	—	—	—	—
	12.12%	1.90%	8.60%	6.20%	-0.80%	2.50%	-0.80%	3.10%	8.00%	—
	20.03%	11.70%	57.20%	-3.40%	-64.00%	373.20%	284.30%	-79.10%	27.00%	—
	—	848.02	1,267	—	—	—	—	—	—	—
	—	0.87	1.39	—	—	—	—	—	—	—
	—	0.00	0.00	—	—	—	—	—	—	—
	—	-1,102	-538.85	—	—	—	—	—	—	—
	—	15.3	6.4	—	—	—	—	—	—	—
Balance sheet
	—	4,324	4,108	—	—	—	—	—	—	—
	—	3,785	3,606	—	—	—	—	—	—	—
	—	1,102	538.85	—	—	—	—	—	—	—
	—	273.11	292.55	—	—	—	—	—	—	—
	—	457.55	481.74	—	—	—	—	—	—	—
	—	54.38	43.05	—	—	—	—	—	—	—
	—	273.51	269.54	—	—	—	—	—	—	—
	—	570.22	708.26	—	—	—	—	—	—	—
	—	1,779	1,905	—	—	—	—	—	—	—
	—	0.00	0.00	—	—	—	—	—	—	—
	—	0.00	0.00	—	—	—	—	—	—	—
	—	0.00	0.00	—	—	—	—	—	—	—
	—	2,285	1,951	—	—	—	—	—	—	—
Cash flow
	—	903.30	1,290	—	—	—	—	—	—	—
	—	396.98	-45.81	—	—	—	—	—	—	—
	—	-737.08	-769.42	—	—	—	—	—	—	—
	—	55.28	23.02	—	—	—	—	—	—	—

Metric	Q2 FY27	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24
Income statement
	1,180	924.42	989.15	1,023	973.63	804.83	966.08	946.36	1,000	811.00	910.87	804.98
	72.77	61.63	35.71	31.82	31.27	43.76	39.46	35.06	32.19	35.85	29.87	28.34
	1,253	986.05	1,025	1,054	1,005	848.59	1,006	981.42	1,032	846.85	940.74	833.32
	795.10	648.07	655.74	676.52	656.89	570.02	650.64	675.07	698.23	598.36	674.43	604.90
	116.90	59.87	101.47	70.10	107.07	121.43	108.35	91.93	137.25	133.33	192.29	87.52
	279.04	378.62	228.39	217.27	232.71	232.07	291.40	164.23	216.74	172.74	255.74	162.52
	170.19	159.04	164.75	151.88	138.05	152.57	152.97	124.74	150.71	151.28	172.83	141.35
	0.49	0.97	0.61	1.19	0.51	0.42	0.58	0.09	0.27	0.37	0.77	0.32
	15.02	15.84	13.17	20.32	17.43	15.52	14.72	18.80	16.86	16.41	18.10	17.11
	171.70	155.77	140.79	154.05	150.36	113.54	136.03	180.00	153.78	137.49	133.60	132.15
	457.58	337.98	369.12	377.89	348.01	278.57	354.90	306.35	334.01	248.49	266.31	228.42
	0.00	0.00	0.00	0.00	2.64	0.00	0.00	—	4.69	—	2.40	-163.31
	457.58	337.98	369.12	377.89	350.65	278.57	354.90	306.35	338.70	248.49	268.71	65.11
	122.96	84.65	94.18	100.71	95.65	73.87	94.76	77.77	90.01	66.84	75.63	19.62
	334.62	253.33	274.94	277.18	255.00	204.70	260.14	228.58	248.69	181.65	193.08	45.49
	19.76	14.95	16.23	16.36	14.92	12.08	15.35	13.49	14.45	10.72	11.39	9.88
Key metrics
	473.09	354.79	382.90	399.40	368.59	294.51	370.20	325.24	355.83	265.27	287.58	82.54
	40.10%	38.40%	38.70%	39.10%	37.90%	36.60%	38.30%	34.40%	35.60%	32.70%	31.60%	10.30%
	28.40%	27.40%	27.80%	27.10%	26.20%	25.40%	26.90%	24.20%	24.90%	22.40%	21.20%	5.70%
	21.30%	—	14.70%	—	17.70%	—	16.20%	—	—	—	—	—
	21.20%	14.90%	2.40%	8.10%	-2.60%	-0.80%	6.10%	17.60%	—	—	—	—
	31.20%	23.80%	5.70%	21.30%	2.50%	12.70%	34.70%	402.50%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18
Income statement
	4,116	3,790	3,723	3,407	3,216	3,218	3,194	3,225	3,129	2,896
	201.93	142.56	142.56	123.48	101.52	76.22	110.19	77.56	101.48	53.52
	4,318	3,933	3,866	3,531	3,318	3,294	3,304	3,302	3,230	2,949
	2,775	2,559	2,622	2,578	2,485	2,532	2,582	2,655	2,571	2,426
	348.34	400.07	470.86	504.99	394.35	552.47	452.64	474.38	682.07	510.27
	1,103	910.44	845.11	853.08	788.43	729.44	880.11	868.92	645.89	788.42
	645.86	607.25	579.70	624.39	594.99	610.23	614.69	628.55	537.20	523.40
	3.26	2.73	1.31	1.80	1.81	1.99	3.53	6.34	0.55	0.19
	64.35	66.44	66.79	69.68	65.77	68.19	79.28	82.68	48.59	37.99
	622.31	558.74	607.30	593.78	571.91	555.71	578.87	629.81	631.32	599.10
	1,543	1,374	1,244	952.65	833.35	761.87	722.33	646.99	658.82	523.78
	0.00	2.64	4.69	-143.61	-0.97	11.58	-172.60	-324.49	4.89	17.80
	1,543	1,376	1,248	809.04	832.38	773.45	549.73	322.50	663.71	541.58
	402.50	364.41	329.38	224.35	227.68	396.87	192.17	212.45	238.35	189.60
	1,140	1,012	919.06	584.69	607.75	1,691	357.56	110.05	425.36	351.98
	67.30	59.00	54.01	34.51	35.70	22.23	21.11	6.50	25.11	—
Key metrics
	1,610	1,445	1,317	880.52	899.96	843.63	632.54	411.52	712.85	579.76
	39.12%	38.10%	35.40%	25.80%	28.00%	26.20%	19.80%	12.80%	22.80%	20.00%
	27.70%	26.70%	24.70%	17.20%	18.90%	52.50%	11.20%	3.40%	13.60%	12.20%
	—	54.80%	56.80%	—	—	—	—	—	—	—
	11.52%	1.80%	9.30%	5.90%	0.00%	0.70%	-1.00%	3.10%	8.00%	—
	20.21%	10.10%	57.20%	-3.80%	-64.00%	372.80%	224.90%	-74.10%	20.80%	—
	—	826.14	1,257	—	—	—	—	—	—	—
	—	0.87	1.39	—	—	—	—	—	—	—
	—	0.00	0.00	—	—	—	—	—	—	—
	—	-1,066	-536.22	—	—	—	—	—	—	—
	—	14.8	5.1	—	—	—	—	—	—	—
Balance sheet
	—	4,275	4,101	—	—	—	—	—	—	—
	—	3,722	3,576	—	—	—	—	—	—	—
	—	1,066	536.22	—	—	—	—	—	—	—
	—	273.11	292.55	—	—	—	—	—	—	—
	—	430.35	463.17	—	—	—	—	—	—	—
	—	54.40	43.05	—	—	—	—	—	—	—
	—	273.51	269.54	—	—	—	—	—	—	—
	—	549.65	704.00	—	—	—	—	—	—	—
	—	1,757	1,901	—	—	—	—	—	—	—
	—	0.00	0.00	—	—	—	—	—	—	—
	—	0.00	0.00	—	—	—	—	—	—	—
	—	0.00	0.00	—	—	—	—	—	—	—
	—	2,241	1,949	—	—	—	—	—	—	—
Cash flow
	—	881.42	1,280	—	—	—	—	—	—	—
	—	385.25	-36.54	—	—	—	—	—	—	—
	—	-737.07	-769.42	—	—	—	—	—	—	—
	—	55.28	23.02	—	—	—	—	—	—	—

Compounded growth

Standalone

Sales CAGR 3Y: +5.62%
Sales CAGR 5Y: +3.48%
Profit CAGR 3Y: +18.52%
Profit CAGR 5Y: +23.13%
Sales YoY (TTM): +11.52%
Profit YoY (TTM): +20.21%

Consolidated

Sales CAGR 3Y: +5.53%
Sales CAGR 5Y: +3.62%
Profit CAGR 3Y: +19.26%
Profit CAGR 5Y: +23.67%
Sales YoY (TTM): +12.12%
Profit YoY (TTM): +20.03%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 75.00%

Quarter	September 2026	June 2026
Promoter %	75.00%	75.00%

Holder	Type	Holding	Previous	Change
GLAXO GROUP LIMITED	Promoter	35.99%	35.99%	0.00%
GLAXOSMITHKLINE PTE LIMITED	Promoter Group	28.10%	28.10%	0.00%
ESKAYLAB LIMITED	Promoter Group	6.94%	6.94%	0.00%
BURROUGHS WELLCOME INTERNATIONAL LIMITED	Promoter Group	3.97%	3.97%	0.00%
NIPPON LIFE INDIA TRUSTEE LTD-A/C NIPPON INDIA NIF	Public	1.05%	—	—
QUANT MUTUAL FUND-QUANT ELSS TAX SAVER FUND	Public	1.01%	—	—
FOREIGN BANK	Public	0.00%	0.00%	0.00%
FOREIGN INSTITUTIONAL INVESTORS	Public	0.00%	0.00%	0.00%

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Sun Pharmaceutical Industries Ltd.	4,26,112	1,776.00	38.78	17.90%	+12.13% TTM	+4.79% TTM	+4.92%
Divi's Laboratories Ltd.	2,66,424	10,036.00	91.09	19.00%	+16.35% TTM	+26.84% TTM	+47.61%
Torrent Pharmaceuticals Ltd.	1,79,908	4,730.00	85.71	9.10%	+42.06% TTM	-1.92% TTM	+32.24%
Laurus Labs Limited	1,24,601	2,306.10	93.53	19.70%	+23.03% TTM	+95.38% TTM	+134.59%
Zydus Lifesciences Limited	1,18,703	1,190.00	25.85	19.20%	+21.11% TTM	-2.51% TTM	+22.32%
Dr. Reddy's Laboratories Ltd.	1,14,513	1,372.00	41.50	13.90%	-3.53% TTM	-51.90% TTM	+14.26%
Cipla Ltd.	1,13,110	1,400.10	39.63	14.90%	-0.74% TTM	-47.48% TTM	-6.88%
Mankind Pharma Limited	1,04,631	2,533.15	46.22	13.70%	+13.27% TTM	+27.60% TTM	+6.91%
Aurobindo Pharma Ltd.	97,878	1,701.10	26.38	13.60%	+9.09% TTM	+9.48% TTM	+47.79%
Lupin Ltd	92,145	2,015.00	17.65	28.40%	+24.22% TTM	+20.10% TTM	+0.84%
Glenmark Pharmaceuticals ltd	70,608	2,501.85	39.27	16.20%	+32.94% TTM	+138.48% TTM	+35.48%
Alkem Laboratories Limited	62,054	5,190.00	28.15	18.80%	+13.36% TTM	-5.52% TTM	-8.38%
Abbott India Ltd. S	57,685	27,146.85	35.73	41.90%	+6.29% TTM	+11.18% TTM	-7.56%
Biocon Ltd.	56,061	344.00	134.63	2.90%	+5.70% TTM	-55.37% TTM	-9.53%
Gland Pharma Limited	52,105	3,157.70	46.16	13.70%	+17.57% TTM	+46.55% TTM	+65.09%
Ipca Laboratories Ltd.	50,051	1,973.15	36.40	16.40%	+10.59% TTM	+67.91% TTM	+52.33%
GlaxoSmithkline Pharmaceuticals Ltd.	42,904	2,532.60	37.42	55.40%	+12.12% TTM	+20.03% TTM	-4.84%
Ajanta Pharma Ltd.	41,406	3,313.55	32.79	29.40%	+25.01% TTM	+29.70% TTM	+26.89%
Emcure Pharmaceuticals Limited	41,254	2,174.55	37.75	25.10%	+21.12% TTM	+33.34% TTM	+64.07%
J.B. Chemicals & Pharmaceuticals Lt	38,731	2,412.25	47.77	21.90%	+5.87% TTM	+7.56% TTM	+45.79%
Sai Life Sciences Limited	32,855	1,546.30	90.80	18.10%	—	—	+67.49%
PIRAMAL PHARMA LIMITED	31,659	237.80	-151.21	0.80%	+9.43% TTM	-781.93% TTM	+18.60%
ACUTAAS CHEMICALS LIMITED	30,928	3,777.65	70.51	27.70%	+45.18% TTM	+95.78% TTM	+106.30%
Wockhardt Ltd	30,869	1,899.80	76.22	6.40%	+25.70% TTM	+894.12% TTM	+39.18%
RUBICON RESEARCH LIMITED	28,416	1,716.55	98.59	24.30%	—	—	+164.06%

Filings & corporate actions

Recent announcements

As per attachment4 Nov 2026 · Company Update / Analyst / Investor Meet
Analyst meet Presentation4 Nov 2026 · Company Update / Analyst / Investor Meet
As per attachment3 Nov 2026 · Company Update / Press Release / Media Release
As per attachment3 Nov 2026 · Company Update / Appointment of Statutory Auditor/s
As per attachment3 Nov 2026 · Company Update / Change in Management
outcome of Meeting3 Nov 2026 · Result / Financial Results
Outcome of meeting3 Nov 2026 · Board Meeting / Outcome of Board Meeting
As per attachment28 Oct 2026 · Company Update / Analyst / Investor Meet
Glaxosmithkline Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/11/2026 ,inter alia, to consider and approve As per attachment13 Oct 2026 · Board Meeting / Board Meeting
As per attachment12 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
As per attachment25 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
As per attachment15 Sep 2026 · AGM/EGM / Postal Ballot
Outcome of Postal Ballot15 Sep 2026 · AGM/EGM / Postal Ballot
As per attachment2 Sep 2026 · Company Update / Newspaper Publication
As per attachment1 Sep 2026 · AGM/EGM / Postal Ballot
As per attachment26 Aug 2026 · Company Update / General
The Exchange has sought clarification from GlaxoSmithKline Pharmaceuticals Ltd on August 26, 2026, with reference to Movement in Volume.<BR><BR>The reply is awaited.26 Aug 2026 · Company Update / Clarification
As per attachment19 Aug 2026 · Company Update / General
As per attachment14 Aug 2026 · Company Update / Newspaper Publication
As per attachment13 Aug 2026 · AGM/EGM / Postal Ballot
Transcript6 Aug 2026 · Company Update / Analyst / Investor Meet
IT Refund of Rs 52 crores6 Aug 2026 · Company Update / General
As per attachment5 Aug 2026 · Company Update / Analyst / Investor Meet
As per attachment4 Aug 2026 · Company Update / Newspaper Publication
As per attachment3 Aug 2026 · Company Update / Analyst / Investor Meet
Reappointment of Managing Director3 Aug 2026 · Company Update / Change in Management
As per attachment3 Aug 2026 · Company Update / Resignation of Director
As per attachment3 Aug 2026 · Company Update / Change in Directorate
As per attachment3 Aug 2026 · Company Update / Press Release / Media Release
Presentation3 Aug 2026 · Company Update / Analyst / Investor Meet
Outcome of meeting3 Aug 2026 · Result / Financial Results
Outcome of Meeting3 Aug 2026 · Board Meeting / Outcome of Board Meeting
As per attachment21 Jul 2026 · Company Update / Analyst / Investor Meet
Glaxosmithkline Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/08/2026 ,inter alia, to consider and approve approve and ....21 Jul 2026 · Board Meeting / Board Meeting
As per attachment8 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
As per attachment30 Jun 2026 · AGM/EGM / AGM
As per attachment30 Jun 2026 · AGM/EGM / AGM
As per attachment26 Jun 2026 · Insider Trading / SAST / Closure of Trading Window
As per attachment25 Jun 2026 · Company Update / General
As per attachment9 Jun 2026 · Company Update / Newspaper Publication

Corporate actions

Purpose	Ex date	Record date	Payment date
Final Dividend - Rs. - 57.0000	29 May 2026	29 May 2026	—
Final Dividend - Rs. - 42.0000	30 May 2025	30 May 2025	—
Interim Dividend - Rs. - 12.0000	7 Nov 2024	7 Nov 2024	—

Board meetings

3 Nov 2026 Board Meeting - Financial Results
3 Aug 2026 Board Meeting - Financial Results